Enhertu cancer drug shows enduring results in ongoing clinical trial
The latest results from a Phase II clinial trial into Enhertu shows consistently promising results, with a durable response in patients with various HER2-expressing tumours.
At the beginning of the year, we highlighted Enhertu from AstraZeneca and Daiichi Sankyo as one of the biggest drug approvals of 2022 and to watch for the year ahead, with promising results from early trials.
Now, further results have been released from the DESTINY-PanTumor02 Phase II trial, looking into the efficacy of the drug, which has shown a positive and durable response in patients with multiple HER2-expressing advanced solid tumours.
The trial includes patients with locally advanced, unresectable, or metastatic previously-treated, HER2-expressing solid tumours that are not eligible for curative therapy. This spans biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers.
Enhertu (trastuzumab deruxtecan) is an engineered HER2-directed antibody drug conjugate (ADC), which targets the HER2 tyrosine kinase receptor protein expressed on the surface of certain cells. The protein is involved in normal cell growth, but in cancer cells it can be overexpressed.
The DESTINY-PanTumor02 Phase II trial aims to evaluate the efficacy and safety of Enhertu as a HER2-targeted therapy. Currently, the safety profile of the drug is consistent with other similar trials. The data from the trial is due to be presented at upcoming meetings and submitted to relevant regulatory agencies for further evaluation.
“Enhertu has already demonstrated its potential to improve outcomes for patients with HER2-targetable breast, gastric and lung cancers, and these positive initial results in other tumour settings with significant unmet need are very encouraging. The DESTINY-PanTumor02 results mark an important step forward in our understanding of the potential role of Enhertu across multiple HER2-expressing tumour types.” Stated Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca.
Ken Takeshita, Global Head, R&D of Daiichi Sankyo, added: “The clinically meaningful responses seen in the DESTINY-PanTumor02 trial reaffirm our belief in the potential of Enhertu across multiple HER2-expressing cancers. The results seen so far across multiple cohorts of the trial will inform next steps of our broad development programme as we look to bring this important medicine to as many patients as quickly as possible.”
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance